OUR portfolio

Our investments accelerate growth and stimulate private sector innovation and investment.

Filter by:
  • 1mg

    Online-to-offline healthcare services in India

    Focus areas
    Healthcare Delivery
    Investment type
    Direct equity
    Status
    Exit
    1mg

    Online-to-offline healthcare services in India

    1mg Technologies Private Limited, a digital consumer healthcare platform in India, provides online-to-offline services to help customers access medicines, diagnostics, and tele-consultations. The foundation’s investment accelerated the low-cost delivery of high-quality essential medicines and other healthcare services across India’s underserved regions.
    Website
    Focus areas
    Healthcare Delivery
    Investment type
    Direct equity
    Status
    Exit
    Initial investment
    Series E
    Partnered in
    2020
    Headquarters
    India
  • Abbott

    Expanded rapid COVID-19 testing in LMICs

    Focus areas
    Healthcare Delivery
    Investment type
    Volume guarantee
    Status
    Exit
    Abbott

    Expanded rapid COVID-19 testing in LMICs

    Abbott Laboratories received the foundation’s support to enable the distribution of its Panbio COVID-19 Ag Rapid Test in low- and middle-income countries. The availability of rapid diagnostic tests that are both cost-effective and produce results within 15–20 minutes is critical in combating the spread of the pandemic.
    Website
    Focus areas
    Healthcare Delivery
    Investment type
    Volume guarantee
    Status
    Exit
    Initial investment
    Public
    Partnered in
    2020
    Headquarters
    USA
  • Achaogen

    Antibacterial drug development

    Focus areas
    Life Sciences
    Investment type
    Direct equity
    Status
    Exit
    Achaogen

    Antibacterial drug development

    Achaogen focuses on the R&D and commercialization of antibacterials to combat multi-drug-resistant, Gram-negative infections. The foundation’s investment supports the development of Achaogen’s monoclonal antibody (mAb) discovery platform.
    Focus areas
    Life Sciences
    Investment type
    Direct equity
    Status
    Exit
    Initial investment
    Public
    Partnered in
    2017
    Headquarters
    USA
  • Acrobatiq

    Next-gen adaptive learning solutions

    Focus areas
    U.S. Education & Opportunity
    Investment type
    Direct equity
    Status
    Exit
    Acrobatiq

    Next-gen adaptive learning solutions

    Acrobatiq, a leader in adaptive learning solutions, received the foundation’s support to help grow its next-generation adaptive learning, courseware, and analytics program.
    Website
    Focus areas
    U.S. Education & Opportunity
    Investment type
    Direct equity
    Status
    Exit
    Initial investment
    Series A
    Partnered in
    2015
    Headquarters
    USA
  • Adjuvant Capital

    Global health–focused investment fund

    Focus areas
    Life Sciences
    Investment type
    Fund
    Status
    Active
    Adjuvant Capital

    Global health–focused investment fund

    Adjuvant, a private investment fund focused on late-stage life sciences investments to address global health challenges—including infectious diseases, sexual and reproductive health, and nutrition—received the foundation’s anchor LP support as part of the foundation’s commitment to the Global Health investment model.
    Website
    Focus areas
    Life Sciences
    Investment type
    Fund
    Status
    Active
    Initial investment
    Fund
    Partnered in
    2019
    Headquarters
    USA
    Portfolio news
    Adjuvant Capital Announces $300 Million Venture Fund Designed to Improve Global Public Health
  • Affinivax

    Next-generation pneumococcal vaccine development

    Focus areas
    Life Sciences
    Investment type
    Direct equity
    Status
    Exit
    Affinivax

    Next-generation pneumococcal vaccine development

    Affinivax achieves unprecedented levels of immune response and disease protection by streamlining the process of vaccine design and allowing multiple antigens to be incorporated in a single vaccine.
    Website
    Focus areas
    Life Sciences
    Investment type
    Direct equity
    Status
    Exit
    Initial investment
    Series A
    Partnered in
    2014
    Headquarters
    USA
    Portfolio news
    In 2022, Affinivax was acquired by GSK
  • African Agricultural Capital Fund

    More productive and profitable smallholder farmers

    Focus areas
    Agriculture & Nutrition
    Investment type
    Fund
    Status
    Active
    African Agricultural Capital Fund

    More productive and profitable smallholder farmers

    The African Agricultural Capital Fund provides growth capital to companies that boost the productivity and profitability of smallholder farmers in East Africa.
    Website
    Focus areas
    Agriculture & Nutrition
    Investment type
    Fund
    Status
    Active
    Initial investment
    Fund
    Partnered in
    2011
    Headquarters
    Uganda
  • AgBiome

    Microbe-derived biological and transgenic crop protection products

    Focus areas
    Agriculture & Nutrition
    Investment type
    Direct equity
    Status
    Exit
    AgBiome

    Microbe-derived biological and transgenic crop protection products

    AgBiome focuses on the discovery and development of biological and transgenic products for crop protection. By identifying microbes from a wide variety of sources, AgBiome is harnessing their natural abilities to help crops resist pests and stresses.
    Website
    Focus areas
    Agriculture & Nutrition
    Investment type
    Direct equity
    Status
    Exit
    Initial investment
    Series B
    Partnered in
    2015
    Headquarters
    USA
  • AgTech Accelerator

    Agriculture entrepreneurship startup incubator

    Focus areas
    Agriculture & Nutrition
    Investment type
    Fund
    Status
    Active
    AgTech Accelerator

    Agriculture entrepreneurship startup incubator

    The AgTech Accelerator, a startup incubator based in Research Triangle Park, North Carolina, focuses on fostering entrepreneurship in agriculture. It is supported by a syndicate of investors that includes ARCH Venture Partners, Flagship Ventures, Hatteras Venture Partners, Bayer CropScience, and Syngenta Ventures.
    Website
    Focus areas
    Agriculture & Nutrition
    Investment type
    Fund
    Status
    Active
    Initial investment
    Fund
    Partnered in
    2016
    Headquarters
    USA
  • Alere

    Point-of-care molecular diagnostics

    Focus areas
    Life Sciences
    Investment type
    Debt
    Status
    Exit
    Alere

    Point-of-care molecular diagnostics

    Expand manufacturing capabilities of point-of-care molecular testing for HIV and tuberculosis.
    Website
    Focus areas
    Life Sciences
    Investment type
    Debt
    Status
    Exit
    Initial investment
    Public
    Partnered in
    2013
    Headquarters
    USA